Drug delivery system and method for targeting cancer stem cells
Systems and methods for targeting specific cancer cell subpopulations present in tumor tissue are described. A system can include a first component for specifically targeting cancer stem cells and a second component for specifically targeting differentiated cancer cells. A system can include a drug conjugated to small (e.g., 5-20 nm) nanoparticles, e.g., polyhedral oligomeric silsequioxane nanoparticles. The small nanoparticles can be preferentially taken up by cancer stem cells via macropinocytosis and can release a toxic payload within the cancer stem cells without triggering the efflux pump. A system can include a second component that targets differentiated cancer cells, e.g., a free drug or a drug encapsulated in nanoparticles.
1. A drug delivery system comprising: a first component for targeting cancer stem cells, the first component comprising a first biologically active agent that directly or indirectly affects the cancer stem cells conjugated to a first nanoparticle, the first nanoparticle having a size of from 5 nanometers to 20 nanometers; and a second component for targeting differentiated cancer cells, the second component comprising a second biologically active agent that directly or indirectly affects the differentiated cancer cells, wherein the second biologically active agent is encapsulated in or conjugated to a second nanoparticle having a size of from about 100 nm to about 200 nm, is in the form of a free drug.
2. The drug delivery system of claim 1 , wherein the first nanoparticle comprises a polyhedral oligomeric silsequioxane.
3. The drug delivery system of claim 2 , the polyhedral oligomeric silsequioxane comprising a structure of RSiO 1,5 , in which R is a hydrogen, an alkyl group, an aryl group, a halogen, an alkenyl group, or a combination thereof.
4. The drug delivery system of claim 3 , the polyhedral oligomeric silsequioxane comprising a structure of (RSiO 1,5 ) n in which n has a value of 6, 8, 10, or 12.
5. The drug delivery system of claim 1 , wherein the second biologically active agent is the same as the first biologically active agent.
6. The drug delivery system of claim 1 , wherein the second biologically active agent is different than the first biologically active agent.